Sugi Predict

Sugi Predict / Compounds / SCHEMBL23258347

SCHEMBL23258347

SCHEMBL23258347

Cc1cc(NCCN(C)C)nc(NC(=O)Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ DNM2 P50570 7/20 0.47
▸ EPHX1 P07099 2/20 0.47
▸ EPHX2 P34913 2/20 0.47
▸ KMT2A Q03164 3/20 0.45
▸ PCTP Q9UKL6 1/20 0.45
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ HTT P42858 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ OPRM1 P35372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349616 0.94 NPC1 (0.52) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL18053805 0.94 NPC1 (0.52) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL29486341 0.94 NPC1 (0.52) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL29486342 0.94 NPC1 (0.52) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL29486340 0.94 NPC1 (0.52) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL23258193 0.93 NPC1 (0.51) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL23258644 0.91 KMT2A (0.50) NPC1RAB9ADNM2KMT2AHTT
SCHEMBL23753656 0.90 NPC1 (0.48) NPC1RAB9ADNM2EPHX1EPHX2
SCHEMBL18038053 0.88 KDR (0.53) CA1CA2CA9
SCHEMBL23258152 0.88 NPC1 (0.54) NPC1RAB9AEPHX1EPHX2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 — — US disclosed
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 — — US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 — — US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 — — US disclosed
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-11-11 — — US disclosed
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG NPC1 4224/4885RAB9A 3638/4885DNM2 736/4885
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG NPC1 4224/4885RAB9A 3638/4885DNM2 736/4885
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG NPC1 4224/4885RAB9A 3638/4885DNM2 736/4885
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG NPC1 4224/4885RAB9A 3638/4885DNM2 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.